These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19969101)

  • 1. Rationalizing the chemical space of protein-protein interaction inhibitors.
    Sperandio O; Reynès CH; Camproux AC; Villoutreix BO
    Drug Discov Today; 2010 Mar; 15(5-6):220-9. PubMed ID: 19969101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods.
    Reynès C; Host H; Camproux AC; Laconde G; Leroux F; Mazars A; Deprez B; Fahraeus R; Villoutreix BO; Sperandio O
    PLoS Comput Biol; 2010 Mar; 6(3):e1000695. PubMed ID: 20221258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
    Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
    BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format.
    Hashimoto J; Watanabe T; Seki T; Karasawa S; Izumikawa M; Seki T; Iemura S; Natsume T; Nomura N; Goshima N; Miyawaki A; Takagi M; Shin-Ya K
    J Biomol Screen; 2009 Sep; 14(8):970-9. PubMed ID: 19641222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods.
    Neugebauer A; Hartmann RW; Klein CD
    J Med Chem; 2007 Sep; 50(19):4665-8. PubMed ID: 17705363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I).
    Morelli X; Bourgeas R; Roche P
    Curr Opin Chem Biol; 2011 Aug; 15(4):475-81. PubMed ID: 21684802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focused chemical libraries--design and enrichment: an example of protein-protein interaction chemical space.
    Zhang X; Betzi S; Morelli X; Roche P
    Future Med Chem; 2014 Jul; 6(11):1291-307. PubMed ID: 24773599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imbalance in chemical space: How to facilitate the identification of protein-protein interaction inhibitors.
    Kuenemann MA; Labbé CM; Cerdan AH; Sperandio O
    Sci Rep; 2016 Apr; 6():23815. PubMed ID: 27034268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between intrinsically disordered proteins frequently occurs in a human protein-protein interaction network.
    Shimizu K; Toh H
    J Mol Biol; 2009 Oct; 392(5):1253-65. PubMed ID: 19660471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential use of protein domain pairs as interaction mediators: order and transitivity.
    Itzhaki Z; Akiva E; Margalit H
    Bioinformatics; 2010 Oct; 26(20):2564-70. PubMed ID: 20802208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using peptides to study protein-protein interactions.
    Benyamini H; Friedler A
    Future Med Chem; 2010 Jun; 2(6):989-1003. PubMed ID: 21426115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FPPI: Fusarium graminearum protein-protein interaction database.
    Zhao XM; Zhang XW; Tang WH; Chen L
    J Proteome Res; 2009 Oct; 8(10):4714-21. PubMed ID: 19673500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein-protein interactions using designed molecules.
    Wilson AJ
    Chem Soc Rev; 2009 Dec; 38(12):3289-300. PubMed ID: 20449049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domains mediate protein-protein interactions and nucleate protein assemblies.
    Costa S; Cesareni G
    Handb Exp Pharmacol; 2008; (186):383-405. PubMed ID: 18491061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards the mammalian interactome: Inference of a core mammalian interaction set in mouse.
    Shin CJ; Davis MJ; Ragan MA
    Proteomics; 2009 Dec; 9(23):5256-66. PubMed ID: 19834899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triathlon for energy functions: who is the winner for design of protein-protein interactions?
    Sharabi O; Dekel A; Shifman JM
    Proteins; 2011 May; 79(5):1487-98. PubMed ID: 21365678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of different domain-based methods in protein interaction prediction.
    Ta HX; Holm L
    Biochem Biophys Res Commun; 2009 Dec; 390(3):357-62. PubMed ID: 19800868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proline-rich sequence recognition domains (PRD): ligands, function and inhibition.
    Freund C; Schmalz HG; Sticht J; Kühne R
    Handb Exp Pharmacol; 2008; (186):407-29. PubMed ID: 18491062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.